Histone gene replacement reveals a post-transcriptional role for H3K36 in maintaining metazoan transcriptome fidelity
Abstract
Histone H3 lysine 36 methylation (H3K36me) is thought to participate in a host of co-transcriptional regulatory events. To study the function of this residue independent from the enzymes that modify it, we used a 'histone replacement' system in Drosophila to generate a non-modifiable H3K36 lysine-to-arginine (H3K36R) mutant. We observed global dysregulation of mRNA levels in H3K36R animals that correlates with the incidence of H3K36me3. Similar to previous studies, we found that mutation of H3K36 also resulted in H4 hyperacetylation. However, neither cryptic transcription initiation, nor alternative pre-mRNA splicing, contributed to the observed changes in expression, in contrast with previously reported roles for H3K36me. Interestingly, knockdown of the RNA surveillance nuclease, Xrn1, and members of the CCR4-Not deadenylase complex, restored mRNA levels for a class of downregulated, H3K36me3-rich genes. We propose a post-transcriptional role for modification of replication-dependent H3K36 in the control of metazoan gene expression.
Data availability
-
Histone gene replacement reveals a post-transcriptional role for H3K36 in maintaining metazoan transcriptome fidelityPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE96922).
-
H3K36me3 abcam L3 Nuc Input expt.2225Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147189).
-
H3K36me3 abcam L3 Nuc Input expt.2226Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147190).
-
H3K36me3 abcam L3 Nuc ChIP expt.2259Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147191).
-
H3K36me3 abcam L3 Nuc ChIP expt.2260Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147192).
-
H3K36me1 L3 Nuc Input expt.2402Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147193).
-
H3K36me1 L3 Nuc Input expt.2404Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147194).
-
H3K36me1 L3 Nuc ChIP expt.2400Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147195).
-
H3K36me1 L3 Nuc ChIP expt.2401Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147196).
-
H3 antibody3 L3 Nuc Input expt.2222Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147289).
-
H3 antibody3 L3 Nuc Input expt.2224Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147290).
-
H3 antibody3 L3 Nuc ChIP expt.2241Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147291).
-
H3 antibody3 L3 Nuc ChIP expt.2242Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147292).
-
H3K36me2 W 14-16 hr OR Emb Input expt.2307Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147547).
-
H3K36me2 W 14-16 hr OR Emb Input expt.2308Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147548).
-
H3K36me2 W 14-16 hr OR Emb ChIP expt.2396Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147549).
-
H3K36me2 W 14-16 hr OR Emb ChIP expt.2397Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1147550).
-
H4K16ac(M).L3 Input expt.2402Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1200107).
-
H4K16ac(M).L3 Input expt.2404Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1200108).
-
H4K16ac(M).L3 ChIP expt.2514Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1200109).
-
H4K16ac(M).L3 ChIP expt.2515Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSM1200110).
Article and author information
Author details
Funding
National Institutes of Health (For use of Harvard TRiP lines,R01-GM084947)
- Michael P Meers
- A Gregory Matera
National Cancer Institute (Ruth L. Kirschstein Predoctoral Fellowship,F31-CA177088)
- Michael P Meers
Office of the Director (Epigenomics Roadmap Project,R01-DA036897)
- Brian D Strahl
- Robert J Duronio
- A Gregory Matera
National Institute of Environmental Health Sciences (Intramural Research Program,Z01-ES101987)
- Karen Adelman
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Metrics
-
- 3,873
- views
-
- 837
- downloads
-
- 47
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Chromosomes and Gene Expression
- Neuroscience
Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.
-
- Biochemistry and Chemical Biology
- Chromosomes and Gene Expression
The mRNA 5'-cap structure removal by the decapping enzyme DCP2 is a critical step in gene regulation. While DCP2 is the catalytic subunit in the decapping complex, its activity is strongly enhanced by multiple factors, particularly DCP1, which is the major activator in yeast. However, the precise role of DCP1 in metazoans has yet to be fully elucidated. Moreover, in humans, the specific biological functions of the two DCP1 paralogs, DCP1a and DCP1b, remain largely unknown. To investigate the role of human DCP1, we generated cell lines that were deficient in DCP1a, DCP1b, or both to evaluate the importance of DCP1 in the decapping machinery. Our results highlight the importance of human DCP1 in decapping process and show that the EVH1 domain of DCP1 enhances the mRNA-binding affinity of DCP2. Transcriptome and metabolome analyses outline the distinct functions of DCP1a and DCP1b in human cells, regulating specific endogenous mRNA targets and biological processes. Overall, our findings provide insights into the molecular mechanism of human DCP1 in mRNA decapping and shed light on the distinct functions of its paralogs.